Pregabalin Market Expected to Reach $2.2 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Pregabalin Market," The pregabalin market was valued at $1.6 billion in 2022, and is estimated to reach $2.2 billion by 2032, growing at a CAGR of 3% from 2023 to 2032. North America dominated the market in 2022 owing to advanced healthcare system, substantial R and D investments for other applications, and the presence of major industry players, it is anticipated to grow at a CAGR of 2.5% during the forecast period.

As the world's population ages and the prevalence of chronic diseases such as diabetes and neurological disorders rises, neuropathic pain and fibromyalgia have grown more widespread leading to an increase in adoption of pregabalin and thereby are the pregabalin market trends driving the market expansion.  This increases the need for drugs that effectively treat certain diseases, such as pregabalin. Moreover, the effectiveness of pregabalin in treating disorders including anxiety disorder, has resulted in a rise in off-label prescriptions. This increases pregabalin's total demand and expands its possible market penetration. Pregabalin is usually administered orally as a liquid or in the form of tablets and capsules.  

The ailment that gets treated, the reaction of the patient to the medicine, and additional variables such as age and general health all affect the dosage and length of treatment. Ongoing studies aimed at enhancing pregabalin's safety and effectiveness profiles and investigating novel indications support the market expansion. Novel formulations and combination medicines have the potential to boost pregabalin market opportunity.

The pregabalin market is segmented into type, application, distribution channel, and region. On the basis of type, the market is bifurcated into tablets and capsules and others. The tablets and capsules segment accounted for the largest pregabalin market size in 2022 and is expected to grow with the highest CAGR owing to wide availability of tablets of varying strengths and generic product launches by various manufacturers.

On the basis of application, the market is classified into neuropathic pain, epilepsy, and others. The neuropathic pain segment accounted for the largest share in 2022 and is expected to grow with the highest CAGR due to the fact that when the population becomes more elderly and diabetic, it increases the risk of neuropathic pain among them, therby boosting the pregabalin market growth.

On the basis of distribution channel, the market is classified into hospital pharmacies, drug store and retail pharmacies, and online providers. The drug store and retail pharmacies segment had the largest pregabalin market share in 2022 and is expected to grow with the highest CAGR owing to wide availability of tablets of varyin contributor to the market in 2022, owing to the widespread accessibility and consumer convenience offered by drug stores and retail pharmacies. These outlets serve as primary points of purchase for pharmaceutical products, making them readily available to a broad consumer base. 

However, the online providers segment is expected to register the fastest growth during the pregabalin market forecast period owing to its convenience and accessibility. Online platforms provide a convenient way for consumers to purchase healthcare products, including pregabalin products, without the need to visit physical stores. The ease of ordering, broader product selection, and potential for competitive pricing make online sales an attractive option. 

On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is expected to dominate the pregabalin market share in 2022 owing to its advanced healthcare system, substantial R and D investments, and the presence of major industry players. Moreover, diagnosis, early treatment for epilepsy, anxiety, neuropathic pain owing to the well established healthcare system drives the market.

However, Asia-Pacific is anticipated to grow with the highest CAGR during the pregabalin industry forecast period, owing to the developments in the healthcare industry, rise in R and D activities, as well as well-established presence of domestic companies in the region. Moreover, favourable government policies, regulatory approvals, boost the market in emerging nations.

The report provides a comprehensive pregabalin market analysis of the key players that operate in the global pregabalin market such as Viatris Inc., Cipla, Amneal Pharmaceuticals, Rising Pharmaceutical, Teva Pharmaceutical, Lupin, ScieGen Pharmaceuticals Inc., Zydus, Medley Pharmaceuticals Ltd., and Novartis AG. The key players have adopted key strategies such as products launch to expand their product portfolio. 

Key Market for Stakeholders 

• On the basis of type, the tablets and capsules segment dominated the  pregabalin market size in terms of revenue in 2022 and is anticipated to grow at the fastest CAGR during the forecast period.  

• On the basis of application, the neuropathic pain segment dominated the pregabalin industry  in terms of revenue in 2022 and is also anticipated to grow at the fastest CAGR during the forecast period. 

• On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022 and online providers segment is anticipated to grow at the fastest CAGR during the forecast period.  

• On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.